Aardvark Therapeutics (AARD) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before October 13, 2026 Lead Plaintiff Deadline
Hagens Berman Sobol Shapiro LLP notified investors of a pending securities class action against Aardvark Therapeutics, covering purchasers traceable to the February 13, 2025 IPO documents and holders during the February 13, 2025 to May 14, 2026 class period, with an October 13, 2026 lead plaintiff deadline. The complaint alleges Aardvark concealed that ARD-101, its small-molecule therapy for hyperphagia in Prader-Willi Syndrome, was less safe than represented, including reversible cardiac observations such as QRS prolongation at above-target doses, overstating prospects for the Phase 3 HERO trial and open-label extension.
Key figures
- Ipo date
- on or about February 13, 2025
- Class period
- February 13, 2025 to May 14, 2026
- Lead plaintiff deadline
- October 13, 2026
- Whistleblower reward cap
- up to 30 percent of any successful SEC recovery
- Stock drop fda hold 2026 05 14
- 32.1%
- Stock drop hero pause 2026 02 27
- over 56%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.